Aksoy S,Bulut N,Dizdar O,et al.Pathological characteristics of very young(≤30 years)breast cancer patients:a single-in-stitution experience from Turkey[J].Ann Oncol, 2009,20(4):790.
Maggard MA,O'Co nnell JB,L ane KE,et al.Do young breast cancer patients have worse outcomes[J].Surg Res,2003,113:109-113.
[6]
Goldhirsch A.Progress and promise:highlights of the international expert consensus on the primary therapy of early breast cancer 2007[J].Annals of Oncology,2007,18(7):1133-1144.
Liu M,Law son G,DdosM,et al. Pred ic tive va lue of the fraction of cancer ce lls immuno labeled for pro lifera ting cell nuc lea r antigen or Ki-67 in b iopsies of head and neck carc-Inom as to identify lymph node m etastasis com parison w ith clinical and rad io log icexam ina tions[J].Head Neck,2003,25(4):280.
[10]
Tut VM,Braith waite AL,Angus B,et al.Cyclin D I expression in transitiona l ce ll carcinom a of the b ladder; correlation with p53,wall,pRb and Ki-67[J].Br J Cancer,2001,84(2):270.
[11]
Niewiadomska H,Jeziorski A,Olborski B.The expression of the proliferating antigen Ki67,PCNA and products of suppressor gene p53 in primary invasive ductal breast carcinoma[J].J Exp Clin Cancer Res,1998,17(4):503-510.
[12]
王晨辰,卢振霞.108例乳腺癌Ki-67与激素受体及Her-2表达的相关性分析[ D].2011.
[13]
Potemski P,P1uciennik E,Bednarek AK,et al.Ki-67 expression in operable breast cancer:a comparative study of immunotaining and a real-time RT-PCR assay [J].Pathol Respract,2006,202(7):491-495.
